相关实验视频

Updated: Mar 12, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

优化虫衍生的生物,AIP-2_NTQ48恢复粘膜耐受性,并降低调节结肠癌相关基因表达TNBS诱导的大肠炎

Yan Lu¹, Adrian Ilich², Ivana B Ferreira³

¹Infection and Inflammation Program, QIMR Berghofer, Brisbane, QLD 4006, Australia; Centre for Childhood Nutrition Research, Faculty of Health, Queensland University of Technology South Brisbane, QLD 4101, Australia.

Mucosal immunology

|March 10, 2026

概括

来自虫蛋白质的新型治疗候选者AIP-2NTQ48在治疗性结肠炎 (UC) 中表现有前途. 它恢复免疫平衡,促进组织修复,为UC患者提供潜在的新疗法.

科学领域:

免疫学免疫学免疫学
胃肠病学胃肠病学
药物发现药物发现药物发现

背景情况:

性结肠炎 (UC) 治疗方法已经进步,但恢复自然免疫耐受性仍然具有挑战性.
虫衍生的抗炎蛋白 (AIP) - 2表现出亲耐药性,此前在喘模型中已经注意到.

研究的目的:

在性结肠炎的临床前模型中研究AIP-2及其优化变体AIP-2NTQ48的治疗潜力.
阐明AIP-2NTQ48在调节免疫反应和促进结肠组织修复中的潜在机制.

主要方法:

利用TNBS诱导的性结肠炎在动物中的模型.
给药的重组AIP-2及其优化结构AIP-2NTQ48.
评估了临床结果,组织学损伤,细胞因子 (IL-6,IFN-γ),T细胞种群 (Th1,Th17,Treg) 和信号通路 (TGF-β,IL-10,ICOSL).
进行了转录组学分析,以确定差异表达的基因和途径.

主要成果:

在UC模型中,AIP-2显著降低了体重减轻,结肠损伤和促炎细胞因子.
AIP-2NTQ48进一步抑制了Th1/Th17通路,并通过TGF-β,IL-10和ICOSL信号传递增强了调节性T细胞 (Tregs).
转录组学揭示了TNF受体超级家族基因的调节,TNF-α诱导的基因和阿尔代脱酶 (ALDH) 酶,促进组织修复和抑制与癌症相关的途径.

结论:

AIP-2NTQ48通过重新平衡Treg/Th17细胞并促进结肠组织修复,证明了性结肠炎的显著治疗潜力.
这种工程蛋白质为UC提供了一种新的疾病修饰治疗策略,解决了恢复免疫耐受性的治疗方法的未满足需求.

关键词:

大肠炎是什么意思虫蛋白质是一种虫蛋白质.粘膜的耐受性粘膜的耐受性拉尔德2h2是什么意思监管性T细胞是什么意思

更多相关视频

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...